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Diabetic peripheral neuropathy (DPN) is an important microvascular complication of diabetes mellitus (DM). It is a
major contributor to foot ulceration and lower limb amputation in persons with DM and have also a significant
negative effect on patient's quality of life. This meta-analysis reviews prevalence of DPN among patients with type 1
and 2 DM in Iran. Using PubMed and NLM Gateway (for MEDLINE), Institute of Scientific Information (ISI), and
SCOPUS as the main international electronic data sources, and Iranmedex, Irandoc, and Scientific Information
Database (SID), as the main domestic databases with systematic search capability, we systematically searched surveys,
papers, and reports on the prevalence of DPN (between January 1991 to February 2013). Heterogeneity of reported
prevalence’s between studies was assessed by the Chi-square-based Q test and due to heterogeneity; overall
prevalence of DPN was estimated using random-effect meta-analysis model. We found 304 records; from them a total
of 21 studies comprising 5540 diabetic patients were included. The prevalence of diabetic neuropathy (reported) from
16% to 87%. In overall the prevalence of DPN estimated 53% (95% CI: 41-65) by using random-effect. This study show
that the prevalence of DPN seems very high among the population with diabetes in Iran and more than half of the
patients with DM has any type of diabetic neuropathy.
Keywords: Diabetic peripheral neuropathy, Diabetes mellitus, Systematic review, Meta-analysisIntroduction
One of the major complications of diabetes mellitus
(DM) is represented by the diabetic peripheral neur-
opathy (DPN). Neuropathy is the most common compli-
cation and greatest source of morbidity and mortality in
diabetes patients. It is estimated that the prevalence of
peripheral polyneuropathy in diabetes patients is approxi-
mately 25-50% in developing countries [1,2]. A DPN ac-
count for more hospital admissions than all other diabetic
complications combined and is responsible for 50 – 75%
of non-traumatic amputations [2,3]. Painful DPN is asso-
ciated with a high degree of functional impairment, im-
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Painful DPN ranges from 10% to 20% of patients with
diabetes and from 40% to 50% of those with diabetic
neuropathies [6]. Painful DPN reportedly results in
significantly higher healthcare costs when compared
with age and sex-matched diabetic patients without
DPN [6,7].
Considering the priority of problem and its increasing
co-morbid complication, there is an undeniable need to
prepare primary data for more awareness of stakeholders
and better policy recommendations [8]. To address this
issue, we should provide comprehensive scientific evi-
dence that support policy actions, programs monitoring,
and interventions evaluation [9].
This study aimed to assess the prevalence of DPN
in Iran (between January 1991 to February 2013)
by conducting an up-to-date comprehensive systematic
review and meta-analytic comparison of all available
studies.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Search strategy
The relevant empirical literature was identified by search-
ing several electronic databases: Main domestic databases;
Iran-Medex, Scientific Information Database (SID), Irandoc,
and also in international databases; PubMed and NLM
Gateway (for MEDLINE), Institute of Scientific Informa-
tion (ISI), and SCOPUS, between January 1991 to February
2013.
The search was performed by cross-referencing the
words “Diabetic Neuropathies” OR “Diabetic Neuropathy”
OR “Diabetic Foot” OR “Diabetic Polyneuropathy” OR
“Diabetic Polyneuropathies” OR “Diabetic Neuralgia” OR
“Peripheral Nervous System Diseases and Iran” OR “I.R.
Iran” OR “I R Iran” OR “Persian”.
All Iranian scientific journals that are not listed in the
domestic electronic databases, governmental reports, pro-
jects reports, conferences and reference lists, were also
reviewed by hand searching.
Definition
Diabetic neuropathy is a nerve disorder caused by diabetes
mellitus. Diabetic neuropathy may be diffuse, affecting
several parts of the body, or focal, affecting a specific nerve
and part of the body [1,10].
The typical DPN is a chronic, symmetrical, length-
dependent sensorimotor polyneuropathy (DSPN) and is
thought to be the most common variety [10]. It develops
on (or with) a background of long-standing hypergly-
cemia, associated metabolic derangements (increased
polyol flux, accumulation of advanced glycation end
products, oxidative stress, and lipid alterations among
other metabolic abnormalities) and cardiovascular risk
factors [10,11].
The quality assessment of eligible papers has been
followed independently by two research experts and prob-
able discrepancy between them resolved based on third
expert opinion. Using Cohen’s kappa statistic, agreement
of them in quality assessment was 0.92.
Inclusion and exclusion criteria
We included all available hospital-based or clinic-based
studies. We excluded article with duplicate citation.
Data extraction
Data were collected according to a standard protocol in-
dependently by two authors. Disagreement was resolved
by discussion between them. In cases they could not
reach a consensus, a third author was consulted. The
extracted information from literature included the name
of the first author, the year of publication, the study
region, total sample size, age and sex groups, diabetes
type, the duration of diabetes, reported prevalence and
its 95% confidence interval.Statistical analysis
The reported prevalence is presented as percent and 95%
confidence interval (CI). Heterogeneity of reported preva-
lence’s between studies was assessed by the Chi-square-
based Q test and I square statistics. The result of Q test
was regarded to be statistically significant at P < 0.1. Due
to sever heterogeneity among studies regarding reported
prevalence of DPN in Iran, overall prevalence was esti-
mated using random-effect meta-analysis model (using the
Der-Simonian and Laird method). Forest plot also was used
to present result of meta-analysis schematically. The ana-
lyses were conducted with STATA software, version 11.0.
Results
The flow diagram of the study selection process is
shown in the Figure 1. The search yielded 304 publica-
tions that were related to inclusion criteria. According to
titles, 276 publications were excluded as clearly ineli-
gible, leaving 28 for further review. Where possible, we
obtained copies of the full published version of each
study, which were then carefully assessed against inclu-
sion/exclusion criteria. After reading abstracts, five publi-
cations were excluded at this stage, leaving 23 publications
that were provisionally eligible. Finally after exclusion of
two duplicated publications, 21 studies were fully eligible
for inclusion in this meta-analysis.
Of these 21 studies, 15 had been reported DPN preva-
lence only as totally without considering gender and
diabetes types, while two studies had data on DPN preva-
lence among males and females and also four papers had
distinguished DPN prevalence in both diabetes type 1 and
2. Two studies assessed the prevalence of DPN only in
patients with type 2 diabetes and also one study had been
included type 1 diabetes. Eighteen studies had samples
from both type of diabetes. The extracted data from these
studies are shown separately in Tables 1 and 2.
The Bostani et al. study in Mashhad found highest
prevalence of DPN, with a prevalence of 87.3% [13] and
the lowest DPN prevalence (15.6%) was found in Talaee
et al. study conducted in Kashan [14]. The highest and
lowest DPN prevalence in woman was 70.6% and 51.6%
respectively. The study in Isfahan found the highest
DPN prevalence of 35.5% in men and the lowest preva-
lence of DPN (21%) in men was reported by Afkhami-
Ardekani et al. and Khazai et al. study [17,23].
Only two studies had been reported DPN prevalence
in both type 1 and 2 of diabetes. A study in Hamedan
found prevalence of DPN 21.5% in type 1 diabetes and
49.3% in type 2 diabetes [10]. The other study in Shiraz
had been estimated DPN prevalence in both type 1 and
2 of diabetes 67% and 69% respectively [27]. One study
was conducted only among patients with type 1 of dia-
betes and has been reported DPN overall prevalence as
27.4% [12].
Figure 1 Flow diagram of the study selection process.
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eity among reported prevalence (I2: 99.8%, p-value < 0.01)
and due to heterogeneity, random-effect meta-analysis
was performed. Based on extracted article and random-
effect meta-analysis; overall DPN estimated prevalence
was 53% (95% CI: 41-65). Figure 2 present the forest plot
of eligible articles for estimating DPN prevalence in Iran.
Discussion
This is an updated systematic review of reported preva-
lence of diabetic neuropathy among the Iranian popula-
tion. In our study finally 21 studies were eligible for
inclusion and data about them from overall of Iran
considered for meta-analysis. We found a few studies
about neuropathy among patients with diabetes mellitus
type I and it is not possible to conduct a meta-analysis
of data of this group.
The prevalence of DPN in this meta-analysis estimated
53% in patients with type 2 diabetes. In comparison with
other similar studies in developing countries, this esti-
mated prevalence of DNP in Iran seems significant
higher than those reports [1,2].However the prevalence of DNP in our meta-analysis
was point estimated but it varied from 16% to 87%, this
variation could be justified by the different diagnostic
criteria of diabetic neuropathy, the age of the partici-
pants in each study, duration and severity of diabetes in
their participants as well as the response rate of the
study population.
This frequency is higher that the studies which re-
ported the prevalence of peripheral DPN in developing
countries [1,2].
A multi-center hospital-clinic based study in the UK
the overall prevalence of DPN was reported 32.1% (95%
CI: 30.6-33.6%) in diabetes type II and 22.7% (95% CI:
21.0-24.4%) in DM type I. They found that with increase
of age and duration of DM the prevalence of DPN
increases and the prevalence of peripheral neuropathy
in ≥60 years age group is higher than 50% (100) [32].
In another large community based study in Rochester
was demonstrated that 59% of patients with diabetes
type II and 66% of patients with diabetes type I had
some form of diabetes neuropathy [33]. In another
multi-center study in Italy only 16.5% of patients with
Table 1 The Characteristic of extracted articles for diabetic peripheral neuropathy in Iran
Number Reference Location Year Mean age (SD) Sample
size (n)
Duration
(yr)
Consideration
1 Kiani et al. (2013) [10] Hamadan 2011 53.26 (14.8) Type 1: 79 9.5 (7.2)
Type 2: 521 Type 2
9.2 (7.4)
2 Hasani et al. (2013) [12] Isfahan 2008-2009 11.9 (3.3) T: 146 3.8 (2.9) Only type 1
diabetes
M: 62
F: 84
3 Bostani et al. (2011) [13] Mashhad 2008-2009 53.2 (1.8) T: 110 0-30
4 Talaee et al. (2011) [14] Kashan 2008-2010 - T: 352 -
5 Tabatabei Malazi et al. (2011) [15] Tehran 2004 53 (12) T: 124 10 (8)
6 Cheraghi et al. (2010) [16] Shadegan 2009 ≥30 T: 521 -
7 Afkhami-Ardekani et al. (2009) [17] Yazd 2006-2007 55.9 (10.0) T: 1000 11.7 (6.8) Only type 2
diabetes
M: 457
F: 543
8 Sadeghieh Ahari et al. (2009) [18] Ardebil 2003 52.5 (11.3) T: 110 8 (6.2) Only type 2
diabetes
9 Ghorbani et al. (2008) [19] Isfahan 2003 40 (-) Range: 15-65 T: 446 -
M: 131
F: 315
10 Abbasian et al. (2008) [20] Shahrod - 50.2 (15.2) T: 340* 5.5 (-)
12 Baghani Moghdam et al. (2007) [21] Yazd - 60% ≥50 yr T: 120 -
40% < 50 yr
15 Ghavami et al. (2007) [22] Oromieh 2002-2003 Renge: 40-65 T: 30 -
M: 9
F: 21
11 Khazai et al. (2006) [23] Mashhad 2002 52.2 (-) T: 200 -
M: 134
F: 66
13 Janghorbani et al. (2006) [24] Isfahan 2000-2003 52.7 (9.9) T: 810 8.2 (6.8)
M: 289
F: 521
Type 1: -
Type 2: 810
14 Yazdanpanah et al. (2006) [25] Dena Kohkeloieh 2003 60% ≥60 yr T: 40 -
M: 12
F: 28
Type 1: -
Type 2: 40
16 Madani et al. (2006) [26] Tehran 2003 59.8 (10.1) T: 68 10.3 (6.7)
17 Ranjbar Omrani et al. (2002) [27] Shiraz Retrospective
studying recent
12 years 1990-2002
Type 1 T: 392 11.4 (6.7)
47.5 (10.4) Type 1: 92
Type 2 Type 2: 300
20.4 (12.8)
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Table 1 The Characteristic of extracted articles for diabetic peripheral neuropathy in Iran (Continued)
18 Sarshar et al. (2003) [28] Gonabad 2001 Type 1 T: 162 -
52 (-)
Type 2
23 (-)
19 Tegha et al. (2002) [29] Tehran 1995-1996 - T: 188 -
20 Rezvani et al. (2001) [30] Birjand 1999-2000 ≥30 T: 70 -
21 Habibi Moeini et al. (1999) [31] Eslamshahr - 47 (10) T: 51 -
*0.3% other type of DM.
Table 2 The prevalence and 95% CI of diabetic peripheral neuropathy in extracted studies in Iran
Number Reference Prevalence (%) 95% CI Consideration
1 Kiani et al. (2013) [10] Total: 45.7 Total: 41.6, 49.7
Type 1: 21.5 Type 1: 13.1, 32.2
Type 2: 49.3 Type 2: 44.9, 53.7
2 Hasani et al. (2013) [12] T: 27.4 T: 20.3, 35.4 Only type 1 diabetes
3 Bostani et al. (2011) [13] T: 87.3 T: 84.8, 89.4
4 Talaee et al. (2011) [14] T: 15.6 T: 14.0, 17.2
5 Tabatabei Malazi et al. (2011) [15] T: 38 T: 34.0, 42.0
6 Cheraghi et al. (2010) [16] T: 81.9 T: 80.9, 82.8
7 Afkhami-Ardekani et al. (2009) [17] T: 51.9 T: 48.7, 55.0 Only type 2 diabetes
M: 21 M: 19.0, 23.0
F: 51.6 F: 47.2, 55.8
8 Sadeghieh Ahari et al. (2009) [18] T: 29.1 25.3, 33.1 Only type 2 diabetes
9 Ghorbani et al. (2008) [19] T: 77.4 T: 76.0, 79.0
M: 29.4 M: 21.4, 37.5
F: 70.6 F: 65.1, 75.4
10 Abbasian et al. (2008) [20] T: 77.3 T: 74.8, 79.4 0.3% other type of DM
12 Baghani Moghdam et al. (2007) [21] T: 87 T: 85.0, 89.0
15 Ghavami et al. (2007) [22] T: 76.5 T: 69.9, 83.1
11 Khazai et al. (2006) [23] T: 41.6 T: 38.0, 45.2
M: 21 M: 14.4, 28.7
F: 51.6 F: 38.9, 64.0
13 Janghorbani et al. (2006) [24] T: 75.1 T: 74.1, 76.1
M: 35.5 M: 29.2, 40.4
F: 64.5 F: 60.2, 68.6
14 Yazdanpanah et al. (2006) [25] T: 52.2 T: 44.2, 60.2
16 Madani et al. (2006) [26] T: 63.2 58.0-68.4
17 Ranjbar Omrani et al. (2002) [27] T: 68.8 T: 67.0, 71.0
Type1: 67 Type1: 55.6, 75.8
Type2: 69 Type2: 63.4, 74.2
18 Sarshar et al. (2003) [28] T: 40.7 T: 37.1, 44.2
19 Tegha et al. (2002) [29] T: 35.1 T: 32.1, 38.1
20 Rezvani et al. (2001) [30] T: 44.3 T: 38.8, 50.4
21 Habibi Moeini et al. (1999) [31] T: 33.3 T: 26.8, 39.4
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 99.8%, p = 0.000)
Talaee  (2011)
Study
Sarshar  (2002)
ID
Tabatabei Malazi  (2011)
Bostani  (2011)
Baghani Moghdam  (2006)
Janghorbani  (2006)
Rezvani  (2001)
Tegha  (2002)
Abbasian  (2006)
Sadeghieh Ahari  (2007)
Khazai  (2006)
Ghavami  (2005)
Ghorbani  (2006)
Ranjbar Omrani  (2003)
Habibi Moeini  (1999)
Yazdanpanah  (2005)
Madani  (2003)
Kiani  (2013)
Cheraghi  (2010)
Afkhami-Ardekani  (2010)
Hasani  (2013)
0.53 (0.41, 0.65)
0.16 (0.14, 0.17)
0.41 (0.37, 0.44)
ES (95% CI)
0.38 (0.34, 0.42)
0.87 (0.85, 0.89)
0.87 (0.85, 0.89)
0.75 (0.74, 0.76)
0.44 (0.39, 0.50)
0.35 (0.32, 0.38)
0.77 (0.75, 0.79)
0.29 (0.25, 0.33)
0.42 (0.38, 0.45)
0.76 (0.70, 0.83)
0.77 (0.76, 0.79)
0.69 (0.67, 0.71)
0.33 (0.27, 0.39)
0.52 (0.44, 0.60)
0.63 (0.58, 0.69)
0.46 (0.44, 0.48)
0.82 (0.81, 0.83)
0.21 (0.19, 0.23)
0.27 (0.24, 0.31)
100.00
4.78
%
4.76
Weight
4.76
4.78
4.78
4.78
4.73
4.77
4.78
4.76
4.77
4.72
4.78
4.78
4.73
4.69
4.74
4.78
4.78
4.78
4.77
0 .5 1
Figure 2 Forest plot of DPN prevalence in Iran using random-effect model.
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opathy was borderline and other diabetic participants
had some degrees of neuropathy [34].
On the other hand, the studies, which were included
in this review, had very diversified in the prevalence of
diabetic neuropathy that they reported from 16% in
Tabatabei Malazi et al. to 87% in Baghani Moghdam
et al. This diversity could depend upon the diagnostic
criteria of diabetic neuropathy, the age of the partici-
pants in each study, duration and severity of diabetes in
their participants as well as the response rate of the
study population. Hyperglycemia due to diabetes melli-
tus increases release of cytokines and activates of protein
C kinase and other oxidative stress [35]. The interesting
notice is that these processes are time dependent and
exacerbate with worse glycemic control [36,37].
According to our knowledge this is the second system-
atic review of prevalence of diabetic neuropathy in Iran
which updates results of pervious study [38]. We en-
rolled all studies, which had reported diabetic neur-
opathy in all age groups up to 2013 in Iran.
Limitations
The first is that we could not report the prevalence of
diabetic neuropathy based on its severity. Other one was
that we could not extract enough data for estimating of
aged adjusted prevalence of the diabetic neuropathy and
difference in age of studies population may be one of the
sources of heterogeneity between studies included instudy and discrepancy between the findings of this study
with other studies reported the prevalence of neur-
opathy. The studies, which were also considered for ana-
lysis, might not use the similar criteria for diagnosis of
diabetic neuropathy.
Conclusion
In conclusions it seems that the prevalence of neur-
opathy is very high among the population with diabetes
in Iran and more than half of the patients with DM has
any type of diabetic neuropathy.
The present findings could provide practical informa-
tion on DPN in Iran. These could be useful for better
health policy and more detailed studies in this field. The
presented results also could be used for future comple-
mentary analyses in sub-national, national or even global
levels.
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